Adagene Inc (ADAG) - Total Assets
Based on the latest financial reports, Adagene Inc (ADAG) holds total assets worth $78.26 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adagene Inc - Total Assets Trend (2018–2025)
This chart illustrates how Adagene Inc's total assets have evolved over time, based on quarterly financial data. Also see ADAG market cap overview for the company's overall valuation and market capitalisation.
Adagene Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Adagene Inc's total assets of $78.26 Million consist of 98.9% current assets and 1.1% non-current assets. Review Adagene Inc (ADAG) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.2% |
| Accounts Receivable | $17.35K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Adagene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ADAG stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adagene Inc's current assets represent 98.9% of total assets in 2025, an increase from 95.2% in 2018.
- Cash Position: Cash and equivalents constituted 95.2% of total assets in 2025, up from 29.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Adagene Inc Competitors by Total Assets
Key competitors of Adagene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Adagene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.07 | 2.50 | 7.28 |
| Quick Ratio | 3.07 | 2.50 | 7.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $52.20 Million | $59.29 Million | $185.63 Million |
Adagene Inc - Advanced Valuation Insights
This section examines the relationship between Adagene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.63 |
| Latest Market Cap to Assets Ratio | 2.85 |
| Asset Growth Rate (YoY) | -12.3% |
| Total Assets | $78.26 Million |
| Market Capitalization | $222.66 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Adagene Inc's assets at a significant premium (2.85x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Adagene Inc's assets decreased by 12.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adagene Inc (2018–2025)
The table below shows the annual total assets of Adagene Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $78.26 Million | -12.33% |
| 2024-12-31 | $89.27 Million | -22.86% |
| 2023-12-31 | $115.73 Million | -24.06% |
| 2022-12-31 | $152.40 Million | -19.58% |
| 2021-12-31 | $189.51 Million | +124.90% |
| 2020-12-31 | $84.26 Million | -20.42% |
| 2019-12-31 | $105.89 Million | +94.59% |
| 2018-12-31 | $54.42 Million | -- |
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more